These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 552295)

  • 1. Effect of increased bioavailability of phenytoin tablets on serum phenytoin concentration in epileptic out-patients.
    Neuvonen PJ; Bardy A; Lehtovaara R
    Br J Clin Pharmacol; 1979 Jul; 8(1):37-41. PubMed ID: 552295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of the bioavailability of Polfa phenytoin tablets].
    Lazowski J; Lypka A; Zadrozyńska E; Pakszys W
    Neurol Neurochir Pol; 1978; 12(3):251-5. PubMed ID: 683430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
    Koren G; Brand N; MacLeod SM
    Ther Drug Monit; 1984; 6(1):11-4. PubMed ID: 6710554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum phenytoin levels in epileptic patients who swallowed their phenytoin tablets with or without previous chewing.
    Bielmann P; Levac T
    Eur J Clin Pharmacol; 1978 Nov; 14(3):191-4. PubMed ID: 729613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum phenytoin determination, its value in the treatment of epilepsy].
    Beier R; Zschiesche M
    Psychiatr Neurol Med Psychol (Leipz); 1977 Feb; 29(2):103-12. PubMed ID: 866497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and dissolution of proprietary and generic formulations of phenytoin.
    Soryal I; Richens A
    J Neurol Neurosurg Psychiatry; 1992 Aug; 55(8):688-91. PubMed ID: 1527539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of three phenytoin preparations in healthy subjects and in epileptics.
    Rambeck B; Boenigk HE; Stenzel E
    Eur J Clin Pharmacol; 1977 Dec; 12(4):285-90. PubMed ID: 579344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and pharmacokinetics of phenytoin during pregnancy.
    Lander CM; Smith MT; Chalk JB; de Wytt C; Symoniw P; Livingstone I; Eadie MJ
    Eur J Clin Pharmacol; 1984; 27(1):105-10. PubMed ID: 6489420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients.
    Houghton GW; Richens A; Leighton M
    Br J Clin Pharmacol; 1975 Jun; 2(3):251-6. PubMed ID: 1234505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effectiveness of two oral phenytoin products and chronopharmacokinetics of phenytoin.
    Petker MA; Morton DJ
    J Clin Pharm Ther; 1993 Jun; 18(3):213-7. PubMed ID: 8345007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations.
    Shin JW; Chu K; Jung KH; Lee ST; Moon J; Lee SK
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1017-22. PubMed ID: 25295717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailability of phenytoin. A comparison of two preparations.
    Stewart MJ; Ballinger BR; Devlin EJ; Miller AY; Ramsay AC
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):209-12. PubMed ID: 1243984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum-phenytoin levels in management of epilepsy.
    Richens A; Dunlop A
    Lancet; 1975 Aug; 2(7928):247-8. PubMed ID: 49797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenytoin bioavailability assessed by steady state serum concentrations.
    Halkin H; Gapany M; Dinai Y; Dany S
    Isr J Med Sci; 1985 Apr; 21(4):327-30. PubMed ID: 3997495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study of bioavailabilities of different phenytoin preparations.
    Fukuyama Y; Kitahara H; Goto T
    Brain Dev; 1982; 4(1):35-43. PubMed ID: 7065375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phenytoin intoxication and serum level].
    Beier R; Zschiesche M; Cammann R
    Psychiatr Neurol Med Psychol (Leipz); 1978 Jul; 30(7):414-23. PubMed ID: 704704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of dosage increments on blood phenytoin concentrations.
    Bochner F; Hooper WD; Tyrer JH; Eadie MJ
    J Neurol Neurosurg Psychiatry; 1972 Dec; 35(6):873-6. PubMed ID: 4647859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of four brands of phenytoin tablets.
    Pentikäinen PJ; Neuvonen PJ; Elfving SM
    Eur J Clin Pharmacol; 1975 Dec; 9(2-3):213-8. PubMed ID: 1243985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bio-availability of phenytoin free-acid serum level determinations whilst using a lactose-based tablet-preparation (author's transl)].
    Fritsch G; Haidvogl M; Füger G; Urban C
    Monatsschr Kinderheilkd; 1980 Oct; 128(10):648-50. PubMed ID: 6107823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical and theoretical aspects of phenytoin administration. I. Relationship between dose and plasma concentration.
    Driessen O; Höppener RJ; van der Velde EA
    Eur Neurol; 1980; 19(6):353-65. PubMed ID: 7439208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.